Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Abstract
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) - Drugs In Development, 2022, provides an overview of the Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline landscape.
Peripheral vascular disease (PVD) refers to diseases of the blood vessels (arteries and veins) located outside the heart and brain. Symptoms include painful cramping in hip, thigh or calf muscles after activity, such as walking or climbing stairs (intermittent claudication), leg numbness or weakness, coldness in lower leg or foot, especially when compared with the other side, sores on toes, feet or legs that won't heal, slower growth of toenails and erectile dysfunction in men.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 10, 11, 3, 17 and 4 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.
Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Content
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Overview
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Companies Involved in Therapeutics Development
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Drug Profiles
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Discontinued Products
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Product Development Milestones
Featured News & Press Releases
Jun 28, 2022: JanOne announces an improved formulation of JAN101
Jun 07, 2022: JanOne announces the issuance of U.S. patent covering a method of improving nerve function using JAN101
May 10, 2022: Hemostemix announces its intellectual property is back home
Jul 22, 2021: JanOne selects CPC Clinical Research as trial manager for phase 2b study of JAN101 for peripheral artery disease patients
Feb 10, 2021: Sanifit granted orphan drug designation by the FDA for SNF472 for the treatment of peripheral arterial disease in patients with end-stage kidney disease
Aug 26, 2020: JanOne advances its potential peripheral artery disease and Covid-19 vascular inflammation treatment towards trial readiness
Aug 21, 2020: JanOne to host telebriefing to discuss drug candidate JAN101 for treatment of peripheral artery disease (PAD) and potential applications for COVID-19 vascular complications
Aug 19, 2020: JanOne to present at The LD 500 Virtual Conference
Aug 11, 2020: JanOne completes stable formulation of JAN101 in preparation for its first GMP manufacturing batch to support upcoming clinical trials
Aug 06, 2020: JanOne engages CATO SMS, a world-leading CRO, to assist in the development of JAN101 to treat COVID-19 vascular complications
Aug 04, 2020: JanOne changes internal drug candidate name from TV1001SR to JAN101
Jul 21, 2020: JanOne receives FDA authorization for transfer of Investigational New Drug (IND) application for its Sodium Nitrite tablets
Jul 20, 2020: Sanifit to start new clinical development program of SNF472 in End Stage Kidney Disease patients with Peripheral Artery Disease
Jul 26, 2018: Foresee Pharmaceuticals Announces Results from a Phase 1 Clinical Study, Highlighting Promising Safety, Tolerability and Pharmacokinetic Profile of FP-045, a Potent ALDH2 Activator
Jan 22, 2018: AnGes Submits Application for Marketing Approval to PMDA for HGF gene therapy for Critical Limb Ischemia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects, 2022
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects, 2022 (Contd..1)
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects, 2022 (Contd..2)
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Discontinued Products, 2022
List of Figures
Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) - Drugs In Development, 2022, provides an overview of the Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline landscape.
Peripheral vascular disease (PVD) refers to diseases of the blood vessels (arteries and veins) located outside the heart and brain. Symptoms include painful cramping in hip, thigh or calf muscles after activity, such as walking or climbing stairs (intermittent claudication), leg numbness or weakness, coldness in lower leg or foot, especially when compared with the other side, sores on toes, feet or legs that won't heal, slower growth of toenails and erectile dysfunction in men.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 10, 11, 3, 17 and 4 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.
Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Overview
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Companies Involved in Therapeutics Development
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Drug Profiles
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Discontinued Products
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Product Development Milestones
Featured News & Press Releases
Jun 28, 2022: JanOne announces an improved formulation of JAN101
Jun 07, 2022: JanOne announces the issuance of U.S. patent covering a method of improving nerve function using JAN101
May 10, 2022: Hemostemix announces its intellectual property is back home
Jul 22, 2021: JanOne selects CPC Clinical Research as trial manager for phase 2b study of JAN101 for peripheral artery disease patients
Feb 10, 2021: Sanifit granted orphan drug designation by the FDA for SNF472 for the treatment of peripheral arterial disease in patients with end-stage kidney disease
Aug 26, 2020: JanOne advances its potential peripheral artery disease and Covid-19 vascular inflammation treatment towards trial readiness
Aug 21, 2020: JanOne to host telebriefing to discuss drug candidate JAN101 for treatment of peripheral artery disease (PAD) and potential applications for COVID-19 vascular complications
Aug 19, 2020: JanOne to present at The LD 500 Virtual Conference
Aug 11, 2020: JanOne completes stable formulation of JAN101 in preparation for its first GMP manufacturing batch to support upcoming clinical trials
Aug 06, 2020: JanOne engages CATO SMS, a world-leading CRO, to assist in the development of JAN101 to treat COVID-19 vascular complications
Aug 04, 2020: JanOne changes internal drug candidate name from TV1001SR to JAN101
Jul 21, 2020: JanOne receives FDA authorization for transfer of Investigational New Drug (IND) application for its Sodium Nitrite tablets
Jul 20, 2020: Sanifit to start new clinical development program of SNF472 in End Stage Kidney Disease patients with Peripheral Artery Disease
Jul 26, 2018: Foresee Pharmaceuticals Announces Results from a Phase 1 Clinical Study, Highlighting Promising Safety, Tolerability and Pharmacokinetic Profile of FP-045, a Potent ALDH2 Activator
Jan 22, 2018: AnGes Submits Application for Marketing Approval to PMDA for HGF gene therapy for Critical Limb Ischemia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects, 2022
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects, 2022 (Contd..1)
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects, 2022 (Contd..2)
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Discontinued Products, 2022
List of Figures
Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
Related Report
